1.81
-0.06(-3.21%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.85 |
| Day High | 1.94 |
| Day Low | 1.8 |
| 52-Week High | 8.74 |
| 52-Week Low | 1.05 |
| Volume | 214,368 |
| Average Volume | 1.33M |
| Market Cap | 56.93M |
| PE | -0.81 |
| EPS | -2.24 |
| Moving Average 50 Days | 1.57 |
| Moving Average 200 Days | 2.64 |
| Change | -0.06 |
If you invested $1000 in Acrivon Therapeutics, Inc. Common Stock (ACRV) since IPO date, it would be worth $108.77 as of October 19, 2025 at a share price of $1.81. Whereas If you bought $1000 worth of Acrivon Therapeutics, Inc. Common Stock (ACRV) shares 2 years ago, it would be worth $333.95 as of October 19, 2025 at a share price of $1.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
GlobeNewswire Inc.
Apr 25, 2025 12:00 PM GMT
Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
GlobeNewswire Inc.
Apr 07, 2025 8:05 PM GMT
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
GlobeNewswire Inc.
Mar 19, 2025 12:00 PM GMT
Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-